Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annovis Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing buntanetap for Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative conditions. Recent Form 8-K reports cover operating results, Regulation FD materials, clinical and regulatory updates, material-event disclosure, exhibits, and changes in executive finance leadership.
Proxy materials describe annual-meeting proposals, director elections, stockholder voting procedures, board governance, and the company’s common stock structure. The filings also identify ANVS common stock as a New York Stock Exchange-listed security and provide capital-structure and governance disclosures relevant to the company’s development-stage business.
Annovis Bio director Michael B. Hoffman reported new open-market purchases of company stock. On May 20, 2026, he bought a total of 76,344 shares of Annovis Bio common stock in three open-market transactions at prices between $1.75 and $1.8999 per share.
Following these transactions, Hoffman directly holds 3,364,883 shares of common stock. A separate entry also reports 223,357 shares held indirectly through The 2024 Hoffman Family Trust, over which he has voting and investment power according to the filing footnote.
Annovis Bio, Inc. entered an underwriting agreement for an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants, targeting gross proceeds of about $15 million before expenses. Each share is sold together with nine-tenths of a warrant at a combined price of $1.90.
The warrants cover up to 7,105,500 shares, are immediately exercisable at $2.25 per share, and expire six years after issuance. Annovis plans to use the net proceeds primarily to continue clinical development of its lead drug candidate buntanetap for Alzheimer’s and Parkinson’s disease, and for working capital and general corporate purposes.
Annovis Bio, Inc. is conducting a registered offering of 7,895,000 shares of common stock, each sold with nine-tenths of a warrant, at a combined public offering price of $1.90 per share and accompanying warrant.
The offering includes warrants to purchase up to 7,105,500 shares with a six-year term and a $2.25 exercise price; delivery is expected on or about May 21, 2026. The company estimates net proceeds of approximately $13.8M (assuming no warrant exercises) and states cash and cash equivalents of $14.2M as of March 31, 2026, which it believes funds operations into the fourth quarter of 2026. The prospectus supplement also discloses existing outstanding warrants, stock options and reserved shares that could dilute holders if exercised.
Annovis Bio is offering common stock together with detachable warrants pursuant to this prospectus supplement to its Form S-3 shelf registration. The supplement discloses underwriting arrangements with Canaccord and reiterates that the exact number of shares offered in this supplement is presented in the prospectus language but left blank in the excerpt.
The company reported $14.2M cash as of March 31, 2026, an accumulated deficit of $181.3M, and 34,646,868 shares outstanding as of May 15, 2026. Recent financing included a registered direct sale of 5,263,156 shares and accompanying warrants at $1.90 per unit, generating net proceeds of $9.3M.
Annovis Bio, Inc. reported a sharp increase in spending as it advances late-stage neurology programs and highlighted serious liquidity risk. For the quarter ended March 31, 2026, the company posted a net loss of $17.6 million, compared with $5.5 million a year earlier, driven mainly by higher research and development costs of $16.7 million as its pivotal Phase 3 Alzheimer’s trial and Parkinson’s open-label extension ramped up.
Cash and cash equivalents fell to $14.2 million from $19.5 million at year-end, with operating activities using $9.0 million of cash in the quarter. Management concluded there is substantial doubt about the company’s ability to continue as a going concern, noting existing cash is not sufficient for 12 months after the report date despite recent financings. Subsequent to quarter-end, Annovis raised additional capital, including a $10.0 million gross underwritten unit offering and further at-the-market share sales, but still anticipates ongoing losses as development of lead candidate buntanetap continues.
Annovis Bio reported first quarter 2026 results showing heavier spending as its late-stage programs advanced. Research and development expenses rose to $16.7M from $5.0M a year earlier, driving a net loss of $17.6M compared with $5.5M in the prior-year quarter, or $0.63 per share diluted versus $0.32.
Cash and cash equivalents were $14.2M as of March 31, 2026, down from $19.5M at year-end, while total liabilities increased to $13.1M and stockholders’ equity declined to $3.1M. The company highlighted progress for its oral therapy buntanetap, with its Phase 3 Alzheimer’s trial on track to finish patient randomization in summer 2026 and deliver first top-line data in early 2027, and a Parkinson’s disease open-label extension study now underway.
Annovis Bio, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 17, 2026. The agenda includes electing five directors, ratifying Ernst & Young LLP as auditor, and approving an amendment to the 2019 Equity Incentive Plan.
The plan amendment would raise the total share reserve from 4,000,000 to 5,500,000 shares and increase the maximum individual annual grant limit from 400,000 to 600,000 shares. Stockholders will also vote on advisory proposals covering executive pay and how often to hold future say‑on‑pay votes.
Annovis Bio, Inc. is raising approximately $10 million through an underwritten registered direct offering of 5,263,156 shares of common stock and accompanying warrants to buy 5,263,156 additional shares. Each share-and-warrant combination is priced at $1.90, and the warrants have an exercise price of $2.50 per share, becoming exercisable six months after issuance and expiring about five and a half years later.
The company expects the offering to close on or about April 10, 2026, subject to customary conditions, with Canaccord Genuity acting as underwriter and sole bookrunner. Annovis plans to use the net proceeds primarily to continue Phase 3 clinical development of its lead drug candidate buntanetap for Alzheimer’s disease, as well as for working capital and general corporate purposes.
Annovis Bio, Inc. is conducting a registered direct offering of 5,263,156 shares of common stock paired with warrants to purchase up to 5,263,156 additional shares. Each share is sold together with a warrant at a combined public offering price of $1.90 per pair.
The warrants will be first exercisable six months after issuance, expire five and one-half years from issuance, and have an exercise price of $2.50 per share. The company expects net proceeds of approximately $9.175 million, which it plans to use to continue Phase 3 development of buntanetap for Alzheimer’s disease and for working capital and general corporate purposes. Shares outstanding were 29,269,237 as of April 8, 2026, and the expected post-offering outstanding share count is 34,532,393 assuming full sale of this offering.
Annovis Bio director Michael B. Hoffman made a large open-market purchase of the company’s common stock. On April 2, 2026, he bought 713,800 shares at $2.10 per share, increasing his direct holdings to 3,288,539 shares.
He also has indirect ownership of 223,357 shares held by The 2024 Hoffman Family Trust, over which he has both voting and investment power. The filing shows no derivative securities remaining, so this activity reflects a direct cash investment rather than an options exercise.